A systematic pan-cancer analysis provides a comprehensive understanding of the carcinogenicity of PXDN and suggests that it may be a potential target for tumor immunotherapy, providing a new candidate that could improve the clinical diagnosis and treatment of cancer (25). This evidence concerns the gene PXDN and cancer.